Here's what brokers tip for CSL shares over the next 12 months

CSL Ltd (ASX: CSL) shares are climbing higher into the green in Thursday lunchtime trade.

At the time of writing, the shares are up around 0.5% and changing hands for $122.29 a piece.

Today's uptick means the ASX biotech shares have now climbed around 15% over the past month and have rebounded 33% since a 15-year low in early June.

But there is still a long way for CSL shares to go before they've recouped the huge amount of losses shed over the past 18 months.

The shares are still down around 29% for the year-to-date and are 51% lower than trading prices 12 months ago.

The latest rebound is certainly a step in the right direction. But the question now is, can CSL shares keep climbing higher?

Here's what the experts expect from the biotech stock over the next 12 months.

Buy, sell or hold: Here's what brokers tip for CSL shares

It looks like market sentiment for CSL shares has shifted recently. Previously, brokers were incredibly bullish about the ASX healthcare shares and were confident of a strong upside ahead.

But now it looks like there's a little more caution in the market.

Market Index data shows that the majority of brokers now have a hold rating on CSL shares. The $131.48 target price implies a potential 8% upside at the time of writing.

TradingView data also shows some ratings downgrades. Out of 18 analysts, 10 now have a hold stance on the biotech company's shares, and another eight have a hold or strong hold rating.

The average target price is a little higher at $140.15, which implies a potential 15% upside at the time of writing. But some are still bullish that CSL shares could climb 64% to $199.68 over the next 12 months.

Morgans is one of the more optimistic brokers. It has a buy rating with a price target of $147.59, implying a robust upside ahead. The broker notes that CSL's long-term story remains intact. However, it thinks that a sustained recovery in sentiment may take several quarters to fully materialise while investors wait for clear improvement in the company's financials.

Elsewhere, the team at Macquarie is more cautious. The broker has a lower price target of $114 and a neutral stance. It cites uncertainty across CSL's core plasma and albumin businesses, as well as ongoing competitive pressures.

My view on CSL shares

The latest rebound shows that investors are now looking forward to the company's FY26 results announcement and any sign that management has been able to improve operations. 

I think there is a lot of potential for the company over the next few years. After all, CSL is operating in a high-growth market, and its blood plasma division dominates the market for rare blood disorders and immunoglobulin products. 

Global demand for plasma therapies is strong and growing, too. There is recurring demand and limited competition, which makes CSL well-placed to carve out a significant portion of the market.

I think that once CSL is able to turn around its financials, investor confidence will follow.

The post Here's what brokers tip for CSL shares over the next 12 months appeared first on The Motley Fool Australia.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has recommended CSL and Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026